Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study
<p>Abstract</p> <p>Background</p> <p>Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant increase in health-related quality of l...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-11-01
|
| Series: | Health and Quality of Life Outcomes |
| Online Access: | http://www.hqlo.com/content/8/1/133 |
| _version_ | 1819119425459060736 |
|---|---|
| author | Fredrikson Sten Seeldrayers Pierette Sanders Evert Lehnick Dirk Jongen Peter J Andersson Magnus Speck Joachim |
| author_facet | Fredrikson Sten Seeldrayers Pierette Sanders Evert Lehnick Dirk Jongen Peter J Andersson Magnus Speck Joachim |
| author_sort | Fredrikson Sten |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant increase in health-related quality of life (HR-QoL) in the first 12 months. It is not known whether HR-QoL increases during treatment with GA.</p> <p>Methods</p> <p>197 RRMS patients, 106 without and 91 with prior immunomodulation/immunosuppression, were studied for HR-QoL (Leeds Multiple Sclerosis-QoL [LMS-QoL] scale, score range 0 - 32), fatigue (Fatigue Impact Scale [FIS]) and depressed mood (Beck Depression Inventory-Short Form [BDI-SF]) at baseline and 6 and 12 months after start of GA treatment.</p> <p>Results</p> <p>At 6 and 12 months mean LMS-QoL scores were significantly increased in the treatment-naive patient group (p < 0.001), not in the pre-treated group. At month 12 43% of treatment-naïve patients had improved HR-QoL (increase LMS-QoL score 3 or more points) (p < 0.001). Likewise, mean FIS scores were decreased at months 6 and 12 in the treatment-naïve group (p < 0.01), not in the pre-treated group. In both groups mean BDI-SF scores did not change. No demographic or clinical baseline factor was predictive of HR-QoL increase. HR-QoL changes were zero to negative for patients who had discontinued GA before month 12 (28.4% of patients).</p> <p>Conclusions</p> <p>In RRMS patients without prior immunomodulation/immunosuppression treatment with GA was associated with an increase in HR-QoL in the first 6 months, that was sustained at 12 months. In 4 out of 10 patients HR-QoL improved. Increase in HR-QoL was associated with decrease in fatigue.</p> |
| first_indexed | 2024-12-22T06:04:34Z |
| format | Article |
| id | doaj.art-631d5634fd6c4d5b8063bac799441bb1 |
| institution | Directory Open Access Journal |
| issn | 1477-7525 |
| language | English |
| last_indexed | 2024-12-22T06:04:34Z |
| publishDate | 2010-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Health and Quality of Life Outcomes |
| spelling | doaj.art-631d5634fd6c4d5b8063bac799441bb12022-12-21T18:36:27ZengBMCHealth and Quality of Life Outcomes1477-75252010-11-018113310.1186/1477-7525-8-133Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre studyFredrikson StenSeeldrayers PieretteSanders EvertLehnick DirkJongen Peter JAndersson MagnusSpeck Joachim<p>Abstract</p> <p>Background</p> <p>Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant increase in health-related quality of life (HR-QoL) in the first 12 months. It is not known whether HR-QoL increases during treatment with GA.</p> <p>Methods</p> <p>197 RRMS patients, 106 without and 91 with prior immunomodulation/immunosuppression, were studied for HR-QoL (Leeds Multiple Sclerosis-QoL [LMS-QoL] scale, score range 0 - 32), fatigue (Fatigue Impact Scale [FIS]) and depressed mood (Beck Depression Inventory-Short Form [BDI-SF]) at baseline and 6 and 12 months after start of GA treatment.</p> <p>Results</p> <p>At 6 and 12 months mean LMS-QoL scores were significantly increased in the treatment-naive patient group (p < 0.001), not in the pre-treated group. At month 12 43% of treatment-naïve patients had improved HR-QoL (increase LMS-QoL score 3 or more points) (p < 0.001). Likewise, mean FIS scores were decreased at months 6 and 12 in the treatment-naïve group (p < 0.01), not in the pre-treated group. In both groups mean BDI-SF scores did not change. No demographic or clinical baseline factor was predictive of HR-QoL increase. HR-QoL changes were zero to negative for patients who had discontinued GA before month 12 (28.4% of patients).</p> <p>Conclusions</p> <p>In RRMS patients without prior immunomodulation/immunosuppression treatment with GA was associated with an increase in HR-QoL in the first 6 months, that was sustained at 12 months. In 4 out of 10 patients HR-QoL improved. Increase in HR-QoL was associated with decrease in fatigue.</p>http://www.hqlo.com/content/8/1/133 |
| spellingShingle | Fredrikson Sten Seeldrayers Pierette Sanders Evert Lehnick Dirk Jongen Peter J Andersson Magnus Speck Joachim Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study Health and Quality of Life Outcomes |
| title | Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study |
| title_full | Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study |
| title_fullStr | Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study |
| title_full_unstemmed | Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study |
| title_short | Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study |
| title_sort | health related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate a prospective observational international multi centre study |
| url | http://www.hqlo.com/content/8/1/133 |
| work_keys_str_mv | AT fredriksonsten healthrelatedqualityoflifeinrelapsingremittingmultiplesclerosispatientsduringtreatmentwithglatirameracetateaprospectiveobservationalinternationalmulticentrestudy AT seeldrayerspierette healthrelatedqualityoflifeinrelapsingremittingmultiplesclerosispatientsduringtreatmentwithglatirameracetateaprospectiveobservationalinternationalmulticentrestudy AT sandersevert healthrelatedqualityoflifeinrelapsingremittingmultiplesclerosispatientsduringtreatmentwithglatirameracetateaprospectiveobservationalinternationalmulticentrestudy AT lehnickdirk healthrelatedqualityoflifeinrelapsingremittingmultiplesclerosispatientsduringtreatmentwithglatirameracetateaprospectiveobservationalinternationalmulticentrestudy AT jongenpeterj healthrelatedqualityoflifeinrelapsingremittingmultiplesclerosispatientsduringtreatmentwithglatirameracetateaprospectiveobservationalinternationalmulticentrestudy AT anderssonmagnus healthrelatedqualityoflifeinrelapsingremittingmultiplesclerosispatientsduringtreatmentwithglatirameracetateaprospectiveobservationalinternationalmulticentrestudy AT speckjoachim healthrelatedqualityoflifeinrelapsingremittingmultiplesclerosispatientsduringtreatmentwithglatirameracetateaprospectiveobservationalinternationalmulticentrestudy |